The Role of the Advanced Practitioner in Maintaining Adherence in Patients on Oral Oncolytics
Kimberly M. Hicks,(1) PharmD, MHA, Diane Cope,(2) PhD, ARNP-BC, AOCNP®, John Novak,(3) CHA, PA-C, and Susan Scherer,(4) RN, BSN, OCN
(1)HHCS Health Group of Companies, Orlando, Florida; (2)Florida Cancer Specialists and Research Institute, Ft. Myers, Florida; (3)Rocky Mountain Cancer Centers, University of Colorado School of Medicine, Aurora, Colorado; (4)RN Cancer Guides Solutions, Tampa, Florida
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Kimberly M. Hicks, PharmD, MHA. E-mail: firstname.lastname@example.org
© 2017 Harborside Press®
In past decades, oral formulations of medications used in the treatment of cancer have become increasingly prevalent. This can be a significant benefit for patients, as it eliminates the need for frequent trips to the infusion center and reduces travel and time away from home, work, and family members. However, making cancer treatments available in oral form transfers most of the responsibility for correct administration of the drug to the patient. With this transfer of responsibility comes the need to support patients in their adherence to the directed regimen. Patient education and communication are crucial. Although helping patients by encouraging adherence should be a team effort, the advanced practitioner is perfectly positioned to be sure that patients receive consistent, tailored support.
For access to the full length article, please sign in